Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04863079
Other study ID # E20210220A
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 1, 2021
Est. completion date April 30, 2024

Study information

Verified date April 2021
Source Tianjin Medical University Cancer Institute and Hospital
Contact Hongjing Jiang, MD, PhD
Phone +8618622221069
Email jianghongjing@tmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to observe and evaluate the efficacy and safety of postoperative adjuvant treatment of pembrolizumab in patients with thoracic esophageal squamous cell carcinoma (ESCC) who have not received neoadjuvant therapy before undergoing R0 resection, and have positive postoperative lymph nodes.


Description:

For patients with thoracic esophageal squamous cell carcinoma (ESCC) who have undergone R0 resection, have not received neoadjuvant therapy, and have positive postoperative lymph nodes, there is no international consensus on whether postoperative adjuvant therapy is required. The JCOG9204 study reported that for patients with ESCC with positive lymph nodes after R0 resection, postoperative adjuvant chemotherapy can improve the disease-free survival (DFS) of the ESCC patients. However, due to the adverse effects of chemotherapy, patients are often difficult to tolerate. We designed a single-arm, open-label, phase II trial of pembrolizumab for adjuvant treatment after R0 resection of thoracic ESCC Patients with lymph node positive. The purpose of this study is to observe and evaluate the efficacy and safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 82
Est. completion date April 30, 2024
Est. primary completion date April 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Histologically confirmed ESCC; 2. Patients have not received neoadjuvant therapy. 3. Thoracic ESCC with R0 resection and positive postoperative lymph nodes; 4. Have a performance status of 0 or 1 on the ECOG Performance Scale; 5. Age 18-70 years old, both men and women; 6. Be willing and able to provide written informed consent/assent for the trial; 7. Demonstrate adequate organ function , all screening labs should be performed within 10 days of treatment initiation; 8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; 9. Be willing to provide postoperative tissue specimens. After tumor recurrence, continue to be willing to provide tissue samples such as needle biopsy. Exclusion Criteria: 1. Neoadjuvant therapy (radiotherapy, immunotherapy, or chemotherapy) for ESCC; 2. Non-R0 resection for ESCC; 3. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug; 4. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); 5. Has severe hypersensitivity and adverse events (=Grade 3) to pembrolizumab and/or any PD-1/PD-L1 inhibitors.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pembrolizumab Injection [Keytruda]
Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.

Locations

Country Name City State
China Tianjin Medical University Cancer Institute and Hospital Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival (OS) Time from the enrollment to death of any cause 24 months
Primary Disease-free survival (DFS) Time from the enrollment to disease relapse after complete resection or death from any cause 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT06389422 - Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis Phase 2
Recruiting NCT06102395 - Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC Phase 3
Recruiting NCT05910710 - Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Not yet recruiting NCT05286320 - Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. Phase 1/Phase 2
Recruiting NCT04955743 - Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Phase 2
Terminated NCT04925986 - Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC Phase 2
Not yet recruiting NCT04333004 - Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy Phase 1/Phase 2
Recruiting NCT04813523 - Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma Phase 2
Recruiting NCT04393883 - A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC) N/A